HRMY

AI Memo

Harmony Biosciences

As of 2026-09-09/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-09 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

BP-205 clinical development milestones • 2026-12-31

Base target: $47 / p=50% prob

Biggest risk

The positive Q2 print and guidance reaffirmation appear partly reflected in the shares, while future upside depends on execution, successful pipeline development, and regulatory outcomes. Verified post-print analyst estimate or target revisions are unavailable.

Invalidation

Break below $35 or thesis failure.

What would change my mind?

Record WAKIX growth, reiterated $1.0-$1.04 billion 2026 revenue guidance, increasing patient counts, and a progressing BP-205 pipeline support continued positive operating momentum [#SEC-8K-2026-08-04].

Research note

Recommendation

—

Confidence

medium

As of

2026-09-09

Base target

$47

p=50%

Bull target

$52

p=25%

Bear target

$35

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

WAKIX commercial execution and 2026 guidance delivery
Pitolisant lifecycle-extension milestones
Record WAKIX growth, reiterated $1.0-$1.04 billion 2026 revenue guidance, increasing patient counts, and a progressing BP-205 pipeline support continued positive operating momentum [#SEC-8K-2026-08-04].

BearKey bullets

BP-205 remains an early-stage clinical program; future efficacy, safety, enrollment, or timing outcomes are uncertain.
Cost of products sold increased to 24.2% of product revenue in Q2, partly due to royalties tied to the Novitium license agreement.
Pitolisant lifecycle expansion depends on clinical execution and regulatory decisions, including the April 1, 2027 target PDUFA date.

WatchKey bullets

BP-205 clinical development milestones

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $47 (p=50%)

Target spread vs base: +10% / -26%

Scenario probabilities

Bull Target: $52 (p=25%)Base Target: $47 (p=50%)Bear Target: $35 (p=25%)

Commentary

Primary-source Q2 disclosures are positive on record WAKIX revenue, reiterated guidance, and BP-205 progress [#SEC-8K-2026-08-04]. Stored earnings context also reports a Q2 EPS and revenue beat, but verified post-print analyst revisions, target changes, options skew, short interest, employee sentiment, and social coverage are unavailable. The recent share-price trend was positive in secondary coverage, but attribution should be treated cautiously.

As of 2026-09-09 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

WAKIX commercial execution and 2026 guidance delivery
Pitolisant lifecycle-extension milestones

Scenarios

Bull Target (Scenario probability)

$52 / p=25% prob

Base Target (Scenario probability)

$47 / p=50% prob

Bear Target (Scenario probability)

$35 / p=25% prob

Analysis 2026-09-09 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.65

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
BP-205 clinical development milestones
Initial Phase 1 single-ascending-dose data showed favorable pharmacokinetic and safety/tolerability profiles. Multiple-ascending-dose data are expected in Q4 2026, followed by further development milestones in 2027 [#SEC-8K-2026-08-04].
Prob 60.00% • Move 10.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

WAKIX commercial execution and 2026 guidance delivery
2026-12-31
Q2 WAKIX net revenue reached $261.3 million, up 30% year over year, with average patients increasing to approximately 8,950. Management reiterated 2026 net revenue guidance of $1.0 billion to $1.04 billion [#SEC-8K-2026-08-04].
Prob 75% • Move 7% • Priced-in 65%

Long-term Catalysts

Months to a year

Pitolisant lifecycle-extension milestones
2027-04-01
The pitolisant gastro-resistant formulation NDA was accepted with a target PDUFA date of April 1, 2027, while pitolisant HD remains on track for Phase 3 topline data in 2027 [#SEC-8K-2026-08-04].
Prob 55% • Move 14% • Priced-in 30%

Risks

BP-205 remains an early-stage clinical program; future efficacy, safety, enrollment, or timing outcomes are uncertain.
Cost of products sold increased to 24.2% of product revenue in Q2, partly due to royalties tied to the Novitium license agreement.
Pitolisant lifecycle expansion depends on clinical execution and regulatory decisions, including the April 1, 2027 target PDUFA date.
Verified analyst revisions, options positioning, short interest, employee sentiment, and social coverage are unavailable.
WAKIX growth or 2026 guidance could fall short if patient additions, demand, or commercial execution weaken.

Peers

Symbol	Summary
BHVN	Same-sector, similar-market-cap comparator, but its development and commercial exposure differ materially from Harmony's WAKIX-centered rare-neurology franchise; read-through is limited.
PVLA	Same-sector, similar-market-cap candidate; the packet does not establish close operating overlap, so it is mainly a broad small-cap biotech comparator.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-09

Loading AI feed…

Symbol

Summary

BHVN

Same-sector, similar-market-cap comparator, but its development and commercial exposure differ materially from Harmony's WAKIX-centered rare-neurology franchise; read-through is limited.

PVLA

Same-sector, similar-market-cap candidate; the packet does not establish close operating overlap, so it is mainly a broad small-cap biotech comparator.